FDA hits Leo Pharma with a CRL for what the biotech says are questions about the 'device component' of eczema candidate
After toiling away for the last few years on a monoclonal antibody to compete with Dupixent in atopic dermatitis, Leo Pharma has been hit with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
